Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial

We recently published 10 Firms Shining Bright in a Bleeding Market. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the best-performing stocks on Monday.

Jazz Pharmaceuticals soared to a new 52-week high on Monday, as investors cheered positive results from the clinical trial of its cancer treatment candidate, Ziihera.

At intra-day trading, the stock jumped to its highest price of $172.91 before trimming gains to finish the day just up by 20.57 percent at $170.09 apiece.

In a statement, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said that it recorded positive results for its phase 3 clinical trial for Ziihera, in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra.

According to Jazz Pharmaceuticals plc (NASDAQ:JAZZ), the trial showed that Ziihera in combination with chemotherapy; as well as in combination with both tislelizumab and chemotherapy; demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy.

The treatment, when combined with both chemotherapy and trastuzumab, also demonstrated clinically meaningful overall survival improvements in enrolled patients.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) plans to submit the data for presentation at a major medical meeting in the first quarter of 2026.

While we acknowledge the potential of JAZZ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.